Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma

Overview

There has been much controversy surrounding the biologic behavior and prognosis of esophageal signet ring cell (SRCs) containing carcinomas. To clarify the biologic behavior of SRCs, the investigators compared the clinicopathologic features and prognosis of SRCs with other adenocarcinomas (ADC) of the esophagus and gastroesophageal junction (GEJ).

Full Title of Study: “Signet Ring Cells in Esophageal and GE Junction Carcinomas Have a More Aggressive Biological Behavior”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: December 2012

Detailed Description

Adenocarcinoma (ADC) of the esophagus and gastroesophageal junction (GEJ) is an aggressive neoplasm and has a poor prognosis. Surgical based treatment has been the treatment of choice for localized esophageal adenocarcinoma. Signet-ring cell carcinoma is a unique histologic subtype of adenocarcinoma characterized by abundant intracellular mucin accumulation and a compressed nucleus displaced toward one extremity of the cell (the so-called signet-ring cell (SRC)). According to the World Health Organisation (WHO), a true signet-ring cell carcinoma (SRCca) is defined as an adenocarcinoma in which the predominant component (more than 50% of the tumor) consists of isolated or small groups of SRC in the stroma. If the tumor contains less than 50% of those cells, it is generally considered as an adenocarcinoma (ADC).

Arms, Groups and Cohorts

  • SRC<50%
    • Adenocarcinoma containing < 50% of signet ring cells
  • SRC>50%
    • Adenocarcinoma containing > 50% of signet ring cells

Clinical Trial Outcome Measures

Primary Measures

  • Cancer specific 5 year survival in SRCC
    • Time Frame: from surgery
    • Cancer specific 5 year survival classified into two groups according to WHO criteria (>50% SRC or <50% SRC)

Participating in This Clinical Trial

Inclusion Criteria

  • Adenocarcinoma R0 resection Primary surgery Exclusion Criteria:

  • Other histology R1 or R2 resection Neoadjuvant therapy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Gasthuisberg
  • Provider of Information About this Clinical Study
    • Principal Investigator: Johnny Moons, RN, MSc, Datamanager – University Hospital, Gasthuisberg
  • Overall Official(s)
    • Philippe Nafteux, MD, Principal Investigator, University Hospital Leuven; Dept. of Thoracic Surgery

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.